search instagram arrow-down

Feb Global Health Readings

Not a global health reading per se (but then, it’s not technically Feb any more either), I open by pointing out the selection of our own Ed Briercheck for the Global Oncology Volunteer of the Month – full article here.  Not a surprise, as Ed’s boundless yet methodical energy makes him high value to any project. But still nice to see him recognized!

On to some articles:

https://www.nytimes.com/2018/03/06/opinion/social-projects-investing-bonds.html

This is a NYT blog piece talking about social bonds, a concept that was brought up at our last Pathway meeting. They are definitely a hot topic in development these days; the essential notion being that gov’t’s offer a bond for private investors who contract to achieve certain goals (children vaccinated, classes offered, etc) via whatever methods they want. If they can make the metric, they get back their money with interest. Interesting stuff, though still relatively novel.

https://www.reuters.com/article/us-india-health/indias-modicare-to-cost-about-1-7-billion-a-year-sources-idUSKBN1FM0QD

The newly announced “Modicare” public insurance scheme for India should be making more headlines as it moves forward – as those in pathway know well, India plays a huge role in the world’s health and economy by dint of its population, and to date has lagged behind the sharp improvement in China in both areas.  But as the Indian economy continues to improve, health should (hopefully) also come along – measures like this has the potential to hasten that rise, depending on how they are implemented.

http://thehill.com/opinion/healthcare/376574-pharmaceutical-corporations-need-to-stop-free-riding-on-publicly-funded

An MSF op-ed piece from The Hill arguing that pharma companies need to pay more for their use of publicly funded research.  I’ll let the editorial speak for itself – for myself, the typical company retort that research is so very expensive falls a bit short in the face of sector that consistently turns some of the highest profits in publicly traded companies.

http://www.who.int/bulletin/volumes/96/3/17-199364/en/

And on a related note, this piece documents the number of countries bypassing pharma patents via TRIPS regulations. A bit of a wonky article, the main takeaway being that this ability (to bypass patent law in the face of public health crisis as per WTO regulations) is being used more often than realized, largely for HIV medications.

Leave a Reply
Your email address will not be published. Required fields are marked *

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: